Multidisciplinary Lifestyle-enhancing Treatment for People With Severe Mental Illness in Sheltered Housing Facilities

NCT ID: NCT03157557

Last Updated: 2020-05-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

177 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-19

Study Completion Date

2020-05-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Introduction and rationale:

Unhealthy eating habits and lack of physical activity are risk factors for many diseases (including metabolic syndrome) and contribute to a shortened lifespan of 15-30 years in people with severe mental illness (SMI). Literature, mainly including short-term hospitalized or outpatients, show strong positive effects of activation on both physical and mental health. However, studies in long-term care are limited. In recent years, implementation of a lifestyle enhancing treatment intervention in clinical settings in "GGz Centraal" has demonstrated to be effective. The question is whether this kind of lifestyle intervention in sheltered housing is applicable and effective.

Objectives:

This research aims to develop an appropriate lifestyle intervention for patients living in sheltered housing services of GGz Centraal, based on input of patients and directly involved. Does applying this lifestyle treatment result in a positive effect in health and quality of life of patients and what is the influence of contextual factors, personal- and disease characteristics?

Study design:

In this intervention study, we use an experimental design. Municipal locations are paired based on the number of participants to generate equal cluster sizes. These paired clusters are randomly allocated to the control or intervention arm by means of a random number generator by an independent person (not involved in this project). At the start of the lifestyle treatment patients in the experimental and control group are invited to participate in the baseline screening. After twelve months, following a post-test on all outcome measures.

Treatment intervention:

The intervention in this study consists of formulating a lifestyle intervention, by patients and directly involved, aimed at enhancing a more active and healthier lifestyle . After formulation of the plan (based on psycho education, nutrition and physical activity), it wil be executed for a twelve month period.

Hypothesis:

Hypotheses is that lifestyle enhancing treatment is associated with improved metabolic health, quality of life and reduced use of medication. Furthermore we expect that movement disorders and disease severity will be negative related in becoming more active.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sample size calculation:

To calculate the sample size we use the effect size on decrease in waist circumference in the previous intervention study (d =0.51) and the same analysis (multiple regression with correction for baseline value's on age, diagnosis and disease severity). To be able to detect the same effect in the current study with a minimum 80% power as a benchmark for a fair test and a significant level of 95% (α = 0.05), a minimum sample of 124 people is required (2 groups of 62). Taking into account a response rate of 73% from the first measurement a sample size of 168 patients is required.

Analyses:

We use multilevel regression to analyze the intervention effect. Possible clustering of data within the residential locations (and thus care teams) is taken into account by using a two-level structure with the first level residential location and the patients as the second. The intervention variable is set as an independent variable against difference scores of outcome variables (T2 minus T1) and corrected for the baseline value of the outcome to prevent regression to the centre. As we are unable to randomize patients individually in the current configuration on personal and disease characteristics (gender, age, diagnosis, disease severity at the start of intervention), these factors will be corrected for in the analyses if they differ significantly(p\<0.05) between intervention and control group, analysed using independent t-tests and chi-squared tests. Characteristics that differ significantly will be included as covariates in the analysis described above. Multicollinearity will be checked with correlation coefficients and collinearity statistics (tolerance and Variance Inflation Factors (VIF) values).

Missing data:

Patients who are hospitalized for more than two months will be excluded from analyses.

If baseline or follow-up data are missing for two or more measures on physical or psychiatric health, patients are excluded from the analysis as insufficient difference scores can be calculated. Patients lacking difference scores on one outcome variable, are excluded from the analysis of that particular variable.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lifestyle Mental Disorders, Severe

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lifestyle treatment

Lifestyle treatment

Group Type EXPERIMENTAL

Lifestyle treatment

Intervention Type BEHAVIORAL

Lifestyle treatment

Treatment as Usual

Treatment as Usual

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lifestyle treatment

Lifestyle treatment

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Severe Mentally Ill patients,
* living in Sheltered Housing facilities

Exclusion Criteria

* Incapacitated patients,
* without informed consent from their legal representative
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GGZ Centraal

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter N van Harten, Prof. Dr.

Role: STUDY_DIRECTOR

GGZ Centraal

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Veldwijk

Ermelo, Gelderland, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

References

Explore related publications, articles, or registry entries linked to this study.

Acil AA, Dogan S, Dogan O. The effects of physical exercises to mental state and quality of life in patients with schizophrenia. J Psychiatr Ment Health Nurs. 2008 Dec;15(10):808-15. doi: 10.1111/j.1365-2850.2008.01317.x.

Reference Type BACKGROUND
PMID: 19012672 (View on PubMed)

Aleman A, Hijman R, de Haan EH, Kahn RS. Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry. 1999 Sep;156(9):1358-66. doi: 10.1176/ajp.156.9.1358.

Reference Type BACKGROUND
PMID: 10484945 (View on PubMed)

Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005 Mar;162(3):441-9. doi: 10.1176/appi.ajp.162.3.441.

Reference Type BACKGROUND
PMID: 15741458 (View on PubMed)

Bassett DR Jr, Cureton AL, Ainsworth BE. Measurement of daily walking distance-questionnaire versus pedometer. Med Sci Sports Exerc. 2000 May;32(5):1018-23. doi: 10.1097/00005768-200005000-00021.

Reference Type BACKGROUND
PMID: 10795795 (View on PubMed)

Bech P, Larsen JK, Andersen J. The BPRS: psychometric developments. Psychopharmacol Bull. 1988;24(1):118-21. No abstract available.

Reference Type BACKGROUND
PMID: 3387515 (View on PubMed)

Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007 Jul;4(7):28-37.

Reference Type BACKGROUND
PMID: 20526405 (View on PubMed)

Callaghan P. Exercise: a neglected intervention in mental health care? J Psychiatr Ment Health Nurs. 2004 Aug;11(4):476-83. doi: 10.1111/j.1365-2850.2004.00751.x.

Reference Type BACKGROUND
PMID: 15255923 (View on PubMed)

Daumit GL, Goldberg RW, Anthony C, Dickerson F, Brown CH, Kreyenbuhl J, Wohlheiter K, Dixon LB. Physical activity patterns in adults with severe mental illness. J Nerv Ment Dis. 2005 Oct;193(10):641-6. doi: 10.1097/01.nmd.0000180737.85895.60.

Reference Type BACKGROUND
PMID: 16208158 (View on PubMed)

Delespaul PH; de consensusgroep EPA. [Consensus regarding the definition of persons with severe mental illness and the number of such persons in the Netherlands]. Tijdschr Psychiatr. 2013;55(6):427-38. Dutch.

Reference Type BACKGROUND
PMID: 23864410 (View on PubMed)

Dingemans PM, Linszen DH, Lenior ME, Smeets RM. Component structure of the expanded Brief Psychiatric Rating Scale (BPRS-E). Psychopharmacology (Berl). 1995 Dec;122(3):263-7. doi: 10.1007/BF02246547.

Reference Type BACKGROUND
PMID: 8748395 (View on PubMed)

Docx L, Sabbe BG, Koning J, Mentzel TQ, van Harten PN, Morrens M. [Instrumental registration of psychomotor symptoms in schizophrenia: has the time come to use the technique in clinical practice?]. Tijdschr Psychiatr. 2015;57(2):148-53. Dutch.

Reference Type BACKGROUND
PMID: 25669955 (View on PubMed)

Farnam CR, Zipple AM, Tyrrell W, Chittinanda P. Health status risk factors of people with severe and persistent mental illness. J Psychosoc Nurs Ment Health Serv. 1999 Jun;37(6):16-21. doi: 10.3928/0279-3695-19990601-15.

Reference Type BACKGROUND
PMID: 10382153 (View on PubMed)

Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull. 2010 Mar;36(2):359-69. doi: 10.1093/schbul/sbn094. Epub 2008 Jul 21.

Reference Type BACKGROUND
PMID: 18644851 (View on PubMed)

Gerlach J, Korsgaard S, Clemmesen P, Lauersen AM, Magelund G, Noring U, Povlsen UJ, Bech P, Casey DE. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand. 1993 Apr;87(4):244-52. doi: 10.1111/j.1600-0447.1993.tb03366.x.

Reference Type BACKGROUND
PMID: 8098178 (View on PubMed)

Hafkenscheid A. Psychometric evaluation of the Nurses Observation Scale for Inpatient Evaluation in The Netherlands. Acta Psychiatr Scand. 1991 Jan;83(1):46-52. doi: 10.1111/j.1600-0447.1991.tb05510.x.

Reference Type BACKGROUND
PMID: 2011956 (View on PubMed)

Kane I, Lee H, Sereika S, Brar J. Feasibility of pedometers for adults with schizophrenia: pilot study. J Psychiatr Ment Health Nurs. 2012 Feb;19(1):8-14. doi: 10.1111/j.1365-2850.2011.01747.x. Epub 2011 May 25.

Reference Type BACKGROUND
PMID: 22070156 (View on PubMed)

Killaspy H, White S, Wright C, Taylor TL, Turton P, Kallert T, Schuster M, Cervilla JA, Brangier P, Raboch J, Kalisova L, Onchev G, Alexiev S, Mezzina R, Ridente P, Wiersma D, Visser E, Kiejna A, Piotrowski P, Ploumpidis D, Gonidakis F, Caldas-de-Almeida JM, Cardoso G, King M. Quality of longer term mental health facilities in Europe: validation of the quality indicator for rehabilitative care against service users' views. PLoS One. 2012;7(6):e38070. doi: 10.1371/journal.pone.0038070. Epub 2012 Jun 4.

Reference Type BACKGROUND
PMID: 22675508 (View on PubMed)

Kozey-Keadle S, Libertine A, Lyden K, Staudenmayer J, Freedson PS. Validation of wearable monitors for assessing sedentary behavior. Med Sci Sports Exerc. 2011 Aug;43(8):1561-7. doi: 10.1249/MSS.0b013e31820ce174.

Reference Type BACKGROUND
PMID: 21233777 (View on PubMed)

Kruisdijk F, Deenik J, Tenback D, Tak E, Beekman AJ, van Harten P, Hopman-Rock M, Hendriksen I. Accelerometer-measured sedentary behaviour and physical activity of inpatients with severe mental illness. Psychiatry Res. 2017 Aug;254:67-74. doi: 10.1016/j.psychres.2017.04.035. Epub 2017 Apr 22.

Reference Type BACKGROUND
PMID: 28456024 (View on PubMed)

Mas-Exposito L, Amador-Campos JA, Gomez-Benito J, Lalucat-Jo L; Research Group on Severe Mental Disorder. The World Health Organization Quality of Life Scale Brief Version: a validation study in patients with schizophrenia. Qual Life Res. 2011 Sep;20(7):1079-89. doi: 10.1007/s11136-011-9847-1. Epub 2011 Feb 3.

Reference Type BACKGROUND
PMID: 21290191 (View on PubMed)

Millier A, Schmidt U, Angermeyer MC, Chauhan D, Murthy V, Toumi M, Cadi-Soussi N. Humanistic burden in schizophrenia: a literature review. J Psychiatr Res. 2014 Jul;54:85-93. doi: 10.1016/j.jpsychires.2014.03.021. Epub 2014 Apr 4.

Reference Type BACKGROUND
PMID: 24795289 (View on PubMed)

Ozemek C, Kirschner MM, Wilkerson BS, Byun W, Kaminsky LA. Intermonitor reliability of the GT3X+ accelerometer at hip, wrist and ankle sites during activities of daily living. Physiol Meas. 2014 Feb;35(2):129-38. doi: 10.1088/0967-3334/35/2/129. Epub 2014 Jan 7.

Reference Type BACKGROUND
PMID: 24399138 (View on PubMed)

Rossler W, Salize HJ, van Os J, Riecher-Rossler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005 Aug;15(4):399-409. doi: 10.1016/j.euroneuro.2005.04.009.

Reference Type BACKGROUND
PMID: 15925493 (View on PubMed)

Sallis JF, Saelens BE. Assessment of physical activity by self-report: status, limitations, and future directions. Res Q Exerc Sport. 2000 Jun;71(2 Suppl):S1-14. No abstract available.

Reference Type BACKGROUND
PMID: 10925819 (View on PubMed)

Santos-Lozano A, Santin-Medeiros F, Cardon G, Torres-Luque G, Bailon R, Bergmeir C, Ruiz JR, Lucia A, Garatachea N. Actigraph GT3X: validation and determination of physical activity intensity cut points. Int J Sports Med. 2013 Nov;34(11):975-82. doi: 10.1055/s-0033-1337945. Epub 2013 May 22.

Reference Type BACKGROUND
PMID: 23700330 (View on PubMed)

Sasaki JE, John D, Freedson PS. Validation and comparison of ActiGraph activity monitors. J Sci Med Sport. 2011 Sep;14(5):411-6. doi: 10.1016/j.jsams.2011.04.003. Epub 2011 May 25.

Reference Type BACKGROUND
PMID: 21616714 (View on PubMed)

Soundy A, Roskell C, Stubbs B, Vancampfort D. Selection, use and psychometric properties of physical activity measures to assess individuals with severe mental illness: a narrative synthesis. Arch Psychiatr Nurs. 2014 Apr;28(2):135-51. doi: 10.1016/j.apnu.2013.12.002. Epub 2013 Dec 19.

Reference Type BACKGROUND
PMID: 24673789 (View on PubMed)

Stanton R, Happell B. Exercise for mental illness: a systematic review of inpatient studies. Int J Ment Health Nurs. 2014 Jun;23(3):232-42. doi: 10.1111/inm.12045. Epub 2013 Sep 30.

Reference Type BACKGROUND
PMID: 24119136 (View on PubMed)

Stubbs B, Firth J, Berry A, Schuch FB, Rosenbaum S, Gaughran F, Veronesse N, Williams J, Craig T, Yung AR, Vancampfort D. How much physical activity do people with schizophrenia engage in? A systematic review, comparative meta-analysis and meta-regression. Schizophr Res. 2016 Oct;176(2-3):431-440. doi: 10.1016/j.schres.2016.05.017. Epub 2016 Jun 1.

Reference Type BACKGROUND
PMID: 27261419 (View on PubMed)

Tenback DE, van Kessel F, Jessurun J, Pijl YJ, Heerdink ER, van Harten PN. [Risk factors for inactivity in patients in long-term care with severe mental illness]. Tijdschr Psychiatr. 2013;55(2):83-91. Dutch.

Reference Type BACKGROUND
PMID: 23408360 (View on PubMed)

Thornicroft G, Tansella M. The balanced care model for global mental health. Psychol Med. 2013 Apr;43(4):849-63. doi: 10.1017/S0033291712001420. Epub 2012 Jul 11.

Reference Type BACKGROUND
PMID: 22785067 (View on PubMed)

van Os J, Kapur S. Schizophrenia. Lancet. 2009 Aug 22;374(9690):635-45. doi: 10.1016/S0140-6736(09)60995-8.

Reference Type BACKGROUND
PMID: 19700006 (View on PubMed)

Vancampfort D, Probst M, Scheewe T, Maurissen K, Sweers K, Knapen J, De Hert M. Lack of physical activity during leisure time contributes to an impaired health related quality of life in patients with schizophrenia. Schizophr Res. 2011 Jul;129(2-3):122-7. doi: 10.1016/j.schres.2011.03.018. Epub 2011 Apr 14.

Reference Type BACKGROUND
PMID: 21493044 (View on PubMed)

Vancampfort D, Rosenbaum S, Schuch F, Ward PB, Richards J, Mugisha J, Probst M, Stubbs B. Cardiorespiratory Fitness in Severe Mental Illness: A Systematic Review and Meta-analysis. Sports Med. 2017 Feb;47(2):343-352. doi: 10.1007/s40279-016-0574-1.

Reference Type BACKGROUND
PMID: 27299747 (View on PubMed)

Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, Rosenbaum S, Correll CU. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015 Oct;14(3):339-47. doi: 10.1002/wps.20252.

Reference Type BACKGROUND
PMID: 26407790 (View on PubMed)

Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015 Apr;72(4):334-41. doi: 10.1001/jamapsychiatry.2014.2502.

Reference Type BACKGROUND
PMID: 25671328 (View on PubMed)

Smit MMC, Waal E, Tenback DE, Deenik J. Evaluating the implementation of a multidisciplinary lifestyle intervention for people with severe mental illness in sheltered housing: effectiveness-implementation hybrid randomised controlled trial. BJPsych Open. 2022 Nov 22;8(6):e201. doi: 10.1192/bjo.2022.600.

Reference Type DERIVED
PMID: 36412504 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL61552.075.17

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.